COVID-19 Should Not Delay Cancer Treatment in Patients With Thoracic Cancer, Data Suggest
Recent exposure to systemic treatment does not increase the risk of 30-day mortality in patients with thoracic cancers and COVID-19.
Recent exposure to systemic treatment does not increase the risk of 30-day mortality in patients with thoracic cancers and COVID-19.
Long-term cumulative exposure to air pollution should be included in assessments of lung cancer risk, according to researchers.
Consent forms could be improved by a patient-centric addendum highlighting key points, a study suggests.
Adding pembrolizumab to chemotherapy can improve survival in extensive-stage small cell lung cancer, a phase 3 study suggests.
Researchers found that 77% of patients had moderate to severe sexual dysfunction.
COVID-19 vaccination does not appear to prevent SARS-CoV-2 infection in patients with lung cancer, but it may prevent severe COVID-19.
Sugemalimab consolidation improved progression-free survival, when compared with placebo, in patients with unresectable, stage III non-small cell lung cancer.
Adding nivolumab to neoadjuvant platinum-based chemotherapy can improve survival in patients with stage IIIA-B non-small cell lung cancer, new data suggest.
Studies have indicated that smoking marijuana may not increase a person’s risk of lung cancer, but robust evidence is lacking.
Though cancer cachexia has been researched extensively, it remains challenging to understand and treat.